Please ensure Javascript is enabled for purposes of website accessibility

Why Heron Therapeutics Stock Is Tanking Today

By George Budwell – Updated Jun 29, 2020 at 11:29AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Its non-opioid painkiller gets a rejection over non-clinical issues.

What happened

Heron Therapeutics (HRTX 5.24%), a commercial-stage biopharma company, is having a tough go of it today. The company's shares were down by 28.6% as of 10:21 a.m. EDT on Monday. 

The culprit? Ahead of the opening bell, Heron announced that the Food and Drug Administration rejected its non-opioid painkiller HTX-011. Heron stated that the drug's regulatory filing was declined because of four non-clinical issues.

A man getting punched in the face.

Image source: Getty Images.

So what

HTX-011 is the company's most important value driver by a wide margin. If this closely watched pain medication ever gains marketing approval in both the U.S. and the EU, it should easily achieve annual sales in excess of $1 billion. That's an enormous revenue stream for a company that ended last week with a market cap of less than $2 billion. As such, it's not exactly surprising to see investors backing away from the stock after this latest regulatory setback. 

Now what

Per today's press release, Heron said that it plans to resubmit the drug's regulatory application as soon as possible. What this means is that the company could have HTX-011 back under consideration by the FDA within the next three months, and an approval in hand by year's end. That's not a surefire outcome by any means, but it is a real possibility.  

All told, this small-cap biotech arguably presents a rather intriguing risk-to-reward ratio in the wake of this double-digit pullback. Aggressive investors, in turn, might want to consider scooping up some shares soon.          

George Budwell has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Heron Therapeutics, Inc. Stock Quote
Heron Therapeutics, Inc.
HRTX
$4.22 (5.24%) $0.21

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
332%
 
S&P 500 Returns
104%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/30/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.